Posted 10/18/11 on GoozNews
Last Friday at 3 p.m., the Agency for Healthcare Research and Quality held a telephone briefing to inform the press and public about the U.S. Preventive Services Task Force recommendation against routine screening of prostate specific antigen (PSA) levels in middle-aged men. The “D” recommendation, now open for public comment, said the harms from false positives and overtreatment of prostate cancer identified by elevated PSA levels outweighed any benefits that would be achieved by the early identification of the relatively small percentage of cases that would lead to metastatic disease and early death.
They posted no slides to go along with the three presentations made at the briefing. They didn’t spell out the names of the men who spoke (I scribbled down Moyer, Chou and LeFebre). And, when they concluded their presentations, they didn’t take questions.